{"id":"bimatoprost-solution-0-03","safety":{"commonSideEffects":[{"rate":"25-45","effect":"Conjunctival hyperemia (redness)"},{"rate":"10-20","effect":"Iris pigmentation increase"},{"rate":"10-20","effect":"Eyelash growth (hypertrichosis)"},{"rate":"10-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Periocular skin pigmentation"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent or slow optic nerve damage and vision loss in glaucoma and ocular hypertension.","oneSentence":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:20.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"},{"name":"Hypotrichosis of the eyelashes"}]},"trialDetails":[{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT05600673","phase":"PHASE1, PHASE2","title":"Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Ahmed Hassan Nouh MD","startDate":"2019-01-01","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT02830776","phase":"EARLY_PHASE1","title":"Topical Bimatoprost for Chemical Blepharoplasty","status":"COMPLETED","sponsor":"Tulane University","startDate":"2016-11","conditions":"Dermatochalasis","enrollment":15},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT01157364","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-23","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":109},{"nctId":"NCT01391273","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":173},{"nctId":"NCT01391286","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-07-01","conditions":"Eyelash Hypotrichosis","enrollment":36},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT03419715","phase":"PHASE2","title":"Topical Bimatoprost in the Treatment of Migraine","status":"UNKNOWN","sponsor":"Manistee Partners","startDate":"2018-01-05","conditions":"Migraine Disorders, Headache Disorders","enrollment":70},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT01068964","phase":"NA","title":"Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":235},{"nctId":"NCT01099774","phase":"PHASE3","title":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-05-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":597},{"nctId":"NCT01023841","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Eyelash Hypotrichosis, Alopecia Areata","enrollment":71},{"nctId":"NCT02176356","phase":"PHASE4","title":"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-30","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":116},{"nctId":"NCT01298700","phase":"PHASE4","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":806},{"nctId":"NCT02505776","phase":"","title":"Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-12-08","conditions":"Eyelash Hypotrichosis","enrollment":1699},{"nctId":"NCT02571712","phase":"PHASE4","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-11-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":750},{"nctId":"NCT03487042","phase":"PHASE4","title":"Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-05","conditions":"Generalized Vitiligo","enrollment":40},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT02059655","phase":"PHASE4","title":"Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2014-11","conditions":"Graves' Ophthalmopathy","enrollment":31},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT01016691","phase":"PHASE2","title":"Safety and Efficacy of a Drug Delivery System in Glaucoma","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01698554","phase":"PHASE3","title":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Idiopathic Eyelash Hypotrichosis","enrollment":464},{"nctId":"NCT01891487","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows","status":"COMPLETED","sponsor":"ATS Clinical Research","startDate":"2013-05","conditions":"Hypotrichosis","enrollment":33},{"nctId":"NCT02170662","phase":"PHASE2","title":"Topical Bimatoprost Effect on Androgen Dependent Hair Follicles","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia","enrollment":33},{"nctId":"NCT01110499","phase":"PHASE2","title":"Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Ocular Hypertension, Primary Open-Angle Glaucoma","enrollment":163},{"nctId":"NCT01200251","phase":"PHASE3","title":"Study of Bimatoprost Gel on Eyelash Growth","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Madarosis, Hypotrichosis","enrollment":20},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT01001195","phase":"PHASE2","title":"Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":165},{"nctId":"NCT01448525","phase":"PHASE4","title":"Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Hypotrichosis","enrollment":88},{"nctId":"NCT01177098","phase":"PHASE3","title":"Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":561},{"nctId":"NCT00907426","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Hypotrichosis","enrollment":368},{"nctId":"NCT00958035","phase":"PHASE4","title":"Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Hypotrichosis","enrollment":89},{"nctId":"NCT01064882","phase":"PHASE2","title":"Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Eyelash Hypotrichosis","enrollment":104},{"nctId":"NCT00541242","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Ocular Hypertension, Glaucoma","enrollment":586},{"nctId":"NCT01202513","phase":"PHASE4","title":"Topical Bimatoprost Solution 0.03%in Stable Vitiligo","status":"WITHDRAWN","sponsor":"Gian Sagar Medical College and Hospital","startDate":"2010-08","conditions":"Vitiligo, Repigmentation","enrollment":20},{"nctId":"NCT00187577","phase":"NA","title":"Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-06","conditions":"Alopecia Areata","enrollment":14},{"nctId":"NCT00651859","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2002-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":111},{"nctId":"NCT00652496","phase":"PHASE2","title":"Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":249},{"nctId":"NCT00355446","phase":"PHASE4","title":"Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2001-07","conditions":"Cataract","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LATISSE®"],"phase":"phase_3","status":"active","brandName":"bimatoprost solution 0.03 %","genericName":"bimatoprost solution 0.03 %","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost solution 0.03% is a small molecule that acts as a prostaglandin F2-alpha receptor agonist. It is used to treat conditions such as Eyelash Hypotrichosis, Open-Angle Glaucoma, and Ocular Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}